ROCHE HOLDING AG

Roche Holding AG’s shares edge higher to CHF 397.4, underscoring its robust earnings, cost‑control strategies and leading Swiss market position in the SMI.

Roche’s solid Q3, driven by Ocrevus and Hemlibra, confirms growth plans and a strategic focus on US‑Asia markets for future innovation and shareholder value.

Roche Holding AG’s latest Q3 earnings show modest stock gains amid a neuro‑immunology push—investors weigh breakthrough data against cautious market sentiment and the company’s core strengths.